Sustained Hypoglycemia Reduction Using eGlycemic Management System® to Manage Insulin Infusion Therapy Among Critical Care Patients

In by Andrea Martucci

Sustained Hypoglycemia Reduction Using eGlycemic Management System® to Manage Insulin Infusion Therapy Among Critical Care Patients

Presentation

Diabetes Technology Society (DTS) Virtual Poster Meeting

Date

June 18, 2020

Authors

Barbara McLean, MN, RN, CCNS-BC, NP-BC, Marina Rabinovich, PharmD, BCPS, Jordan Messler, MD, SFHM, FACP

OBJECTIVE

Identify whether reductions in hypoglycemia have been sustained among critical care patients receiving insulin infusion therapy managed using the technology-enabled eGlycemic Management System® (eGMS®).*

*eGlycemic Management System® is a registered trademark of Glytec, LLC on behalf of Aseko, Inc. All Rights Reserved.

METHOD

Grady Hospital, a 640-bed academic medical  center in Atlanta, Georgia, conducted a retrospective review of critical care patients with persistent hyperglycemia >180 mg/dL who received insulin infusion therapy in an ICU (medical, surgical, cardiovascular neuroscience or burn) or step-down unit.

The primary endpoints were percentages of blood glucose readings (BGs) <40 mg/dL and <70 mg/dL. The review compares patients whose therapy was managed using eGMS® to those
whose therapy was managed using standard protocols (“usual care”). Data was collected for the period of October 2016 through December 2019. (NOTE: (eGMS® was implemented at Grady Hospital the month of December 2016).

This review is in follow up to a previous review in which data was collected for the period of October 2016 through December 2018. Usual care endpoints of 0.44% BGs <40 mg/dL and 2.44% BGs <70 mg/dL were carried forward from the previous review to this review.

RESULT

Reductions in hypoglycemia among critical care patients receiving insulin infusion therapy using eGMS® have been sustained over the three-year period since the system was implemented at Grady Hospital. The average percentage of BGs <40 mg/dL within the eGMS® population was .02% over the initial (previous) review period of October 2016 through December 2018 and was 0.01% over the (extended) follow-up review period of October 2016 through December 2019. This compares to a rate of 0.44% within the usual care population. The average percentage of BGs <70 mg/dL within the eGMS® population was 0.32% over the initial (previous) review period and was 0.31% over the (extended) follow-up review period. This compares to a rate of 2.44%
within the usual care population.

Click Image to Enlarge

Click Image to Enlarge

CONCLUSIONS

Reductions in hypoglycemia among critical care patients receiving insulin infusion therapy can be achieved and sustained effectively and efficiently using the technology-enabled eGlycemic Management System® (eGMS®), with 98% lower incidence of BGs <40 mg/dL when compared to usual care and 87% lower incidence of BGs <70 mg/dL.

References

  1. McLean B , Rabinovich M, Messler J. Sustained Hypoglycemia Reduction Using eGlycemic Management System® to Manage Insulin Infusion Therapy Among Critical Care Patients. DTS Virtual Poster Meeting. June 18, 2020.

ECO #0846-A